

ANNEXURE I

Format to be submitted by listed entity on quarterly basis

1. Name of Listed Entity **-Ajooni Biotech Limited**
 2. Quarter ending **- 31-Mar-2023**

i. Composition Of Board Of Director

T i t l e (M r . / M s)	N a m e o f t h e D i r e c t o r	D I N	P A N	C a t e g o r y (C h a i r p e r s o n / E x e c u t i v e / N o n - E x e c u t i v e / I n d e p e n d e n t / N o m i n e e	S u b C a t e g o r y	I n i t i a l D a t e o f A p p o i n t m e n t	D a t e o f A p p o i n t m e n t	D a t e o f c e s s a t i o n	T e n u r e	D a t e o f B i r t h	W h e t h e r t h e d i r e c t o r i s d i s q u a l i f i e d ?	S t a r t D a t e o f d i s q u a l i f i c a t i o n	E n d D a t e o f d i s q u a l i f i c a t i o n	D e t a i l s o f d i s q u a l i f i c a t i o n	C u r e n t s t a t u s	W h e t h e r s p e c i a l r e s o l u t i o n p a s s e d ? [R e f e r R e g . 1 7 (1 A) o f L i s t i n g R e g u l a t i o n s]	D a t e o f p a s s i n g s p e c i a l r e s o l u t i o n	N o. o f D i r e c t o r s h i p i n l i s t e d e n t i t i e s i n c l u d i n g t h i s l i s t e d e n t i t y [i n r e f e r e n c e t o R e g u l a t i o n 1 7 A (1)]	N o. o f I n d e p e n d e n t D i r e c t o r s h i p i n l i s t e d e n t i t i e s i n c l u d i n g t h i s l i s t e d e n t i t y [i n r e f e r e n c e t o p r o v i s o t o r e	N o. o f f o r m e m b e r s h i p i n A u d i t / S t a k e h o l d e r C o m m i t t e (s) i n c l u d i n g t h i s l i s t e d e n t i t y	N o. o f p o s t o f C h a i r p e r s o n i n A u d i t / S t a k e h o l d e r C o m m i t t e e h e l d i n l i s t e d e n t i t i e s	M e m b e r s h i p i n C o m m i t t e e s o f t h e C o m p a n y	R e m a r k s
---	---	-------------	-------------	--	---	--	---	---	----------------------------	---	---	---	---	---	--	--	--	---	--	---	--	--	---------------------------------

	E S H W A R S I N G H B H A T I A	6 4 0 0 7	P B 8 3 7 9 D			S e p - 2 0 2 2	p- 20 22		b- 19 88							p- 20 22					C, N R C		
M r.	R A M A N D E E P S I N G H	0 7 8 9 6 0 8 8 6	C L I P S 8 7 3 4 C	ID		2 0 - S e p - 2 0 2 2	20 - S e p- 20 22		6 0	24 - J u n- 19 87	N o					Y e s	20 - S e p- 20 22	2	1	1	0	A C, S C, N R C	
M r s .	S I M M I C H H A B R A	0 7 8 7 0 3 9 8	A M U P C 4 0 3 7 B	ID		2 0 - S e p - 2 0 2 2	20 - S e p- 20 22		6 0	07 - D e c - 19 87	N o					Y e s	20 - S e p- 20 22	2	2	2	1	A C, S C, N R C	

Company Remarks	
Whether Regular chairperson appointed	Yes
Whether Chairperson is related to MD or CEO	Yes

ii. Composition of Committees

a. Audit Committee

Sr.	Name of Committee	Category	Chairperson/Member	Date of	Date of
-----	-------------------	----------	--------------------	---------	---------

No.	members			Appointment	Cessation
1	IMTESHWAR SINGH BHATIA	ID	Member	25-Aug-2017	
2	RAMANDEEP SINGH	ID	Member	25-Aug-2017	
3	SIMMI CHHABRA	ID	Chairperson	25-Aug-2017	

Company Remarks	
Whether Regular chairperson appointed	Yes

b. Stakeholders Relationship Committee

Sr. No.	Name of Committee members	Category	Chairperson/Member	Date of Appointment	Date of Cessation
1	IMTESHWAR SINGH BHATIA	ID	Member	25-Aug-2017	
2	RAMANDEEP SINGH	ID	Member	25-Aug-2017	
3	SIMMI CHHABRA	ID	Chairperson	25-Aug-2017	

Company Remarks	
Whether Regular chairperson appointed	Yes

c. Risk Management Committee

Sr. No.	Name of Committee members	Category	Chairperson/Member	Date of Appointment	Date of Cessation
---------	---------------------------	----------	--------------------	---------------------	-------------------

Company Remarks	Risk Management Committee IS NOT APPLICABLE
Whether Regular chairperson appointed	No

d. Nomination and Remuneration Committee

Sr. No.	Name of Committee members	Category	Chairperson/Member	Date of Appointment	Date of Cessation
1	IMTESHWAR SINGH BHATIA	ID	Member	25-Aug-2017	
2	RAMANDEEP SINGH	ID	Member	25-Aug-2017	
3	SIMMI CHHABRA	ID	Chairperson	25-Aug-2017	

Company Remarks	
Whether Regular chairperson appointed	Yes

iii. Meeting of Board of Directors

Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present (All directors including Independent Director)	No. of Independent Directors attending the meeting
14-Feb-2023	Yes	6	6	3
27-Mar-2023	Yes	6	6	3

Company Remarks	
-----------------	--

Maximum gap between any two consecutive (in number of days)	0
---	---

iv. **Meeting of Committees**

Name of the Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors present (All directors including Independent Director)	Number of Independent directors attending the meeting	Number of Members attending the Meeting (Other than Board of Directors)
Audit Committee	14-Feb-2023	Yes	3	3	3	0
Nomination & Remuneration Committee	14-Feb-2023	Yes	3	3	3	0
Stakeholders Relationship Committee	14-Feb-2023	Yes	3	3	3	0

Company Remarks	
Maximum gap between any two consecutive (in number of days) [Only for Audit Committee]	0

v. **Related Party Transactions**

<i>Subject</i>	<i>Compliance status (Yes/No)</i>
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Yes
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes

Disclosure of notes on related party transactions and Disclosure of notes of material related party transactions	
--	--

VI. **Affirmations**

1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. - **Yes**
2. The composition of the following committees is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015
 - a. Audit Committee - **Yes**
 - b. Nomination & remuneration committee - **Yes**

- c. Stakeholdersrelationshipcommittee - **Yes**
- d. Risk management committee (applicable to the top 1000 listed entities) - **Not applicable**
- 3. Thecommitteemembershavebeenmadeawareoftheirpowers,roleandresponsibilitiesasspecifiedinSEBI(Listingobligationsanddisclosurerequirements)Regulations,2015. - **Yes**
- 4. ThemeetingsoftheboardofdirectorsandtheabovecommitteeshavebeenconductedinthemannerasspecifiedinSEBI(Listingobligationsanddisclosurerequirements)Regulations,2015.- **Yes**
- 5. a. Thisreportand/orthereportssubmittedinthepreviousquarterhasbeenplacedbeforeBoardofDirectors.- **Yes**
b. Anycomments/observations/adviceofBoardofDirectorsmaybementionedhere:

Name : **Swati Vijan**
Designation : **Company Secretary**

ANNEXURE II

Format to be submitted by listed entity at the end of the financial year (for the whole of financial year)

I. Disclosure on website in terms of Listing Regulations			
Item	Compliance status (Ye	Company Remark	Website
As per regulation 46(2) of the LODR:			
Details of business	Yes		https://www.ajoonibiote
Terms and conditions of appointment	Yes		https://www.ajoonibiote
Composition of various committees of	Yes		https://www.ajoonibiote
Code of conduct of board of	Yes		https://www.ajoonibiote
Details of establishment of vigil mechanism/	Yes		https://www.ajoonibiote
Criteria of making payments to non-	Yes		https://www.ajoonibiote
Policy on dealing with related party	Yes		https://www.ajoonibiote
Policy for determining 'material' subsidiaries	Yes		https://www.ajoonibiote
Details of familiarization programs imparted	Yes		https://www.ajoonibiote
Email address for grievance redressal and other relevant details entity who are	Yes		https://www.ajoonibiote
Contact information of the designated	Yes		https://www.ajoonibiote
Financial results	Yes		https://www.ajoonibiote
Shareholding pattern	Yes		https://www.ajoonibiote
Details of agreements entered into with the media companies and/or their associates	Not Applicable		
Schedule of analyst or institutional investor meet and presentations made by the listed	Not Applicable		
New name and the old name of the listed	Not		
Advertisements as per regulation 47 (1)	Yes		https://www.ajoonibiote
Credit rating or revision in credit rating	Not		
Separate audited financial statements of	Not		
As per other regulations of the LODR:			
Whether company has provided information under separate section on its website as per Regulation 46(2)	Yes		https://www.ajoonibiote
Materiality Policy as per Regulation 30	Yes		https://www.ajoonibiote
Dividend Distribution policy as per	Yes		https://www.ajoonibiote
It is certified that these contents on the	Yes		
II Annual Affirmations			
Particulars	Regulation Number	Compliance status	Company Remark
<i>Independent director(s) have been appointed in terms of specified criteria of 'independence' and</i>	16(1)(b) & 25(6)	Yes	
<i>Board composition</i>	17(1), 17(1A) & 17(1B)	Yes	
<i>Meeting of Board of directors</i>	17(2)	Yes	
<i>Quorum of Board meeting</i>	17(2A)	Yes	
<i>Review of Compliance Reports</i>	17(3)	Yes	
<i>Plans for orderly succession for appointments</i>	17(4)	Yes	
<i>Code of Conduct</i>	17(5)	Yes	
<i>Fees/compensation</i>	17(6)	Yes	

Minimum Information	17(7)	Yes	
Compliance Certificate	17(8)	Yes	
Risk Assessment & Management	17(9)	Yes	
Performance Evaluation of Independent Directors	17(10)	Yes	
Recommendation of Board	17(11)	Yes	
Maximum number of directorship	17A	Yes	
Composition of Audit Committee	18(1)	Yes	
Meeting of Audit Committee	18(2)	Yes	
Composition of nomination & remuneration committee	19(1) & (2)	Yes	
Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
Meeting of nomination & remuneration committee	19(3A)	Yes	
Composition of Stakeholder Relationship Committee	20(1), 20(2) and 20(2A)	Yes	
Meeting of stakeholder relationship committee	20(3A)	Yes	
Composition and role of risk management committee	21(1), (2), (3), (4)	Not Applicable	
Meeting of Risk Management Committee	21(3A)	Not Applicable	
Vigil Mechanism	22	Yes	
Policy for related party Transaction	23(1), (1A), (5), (6)	Yes	
Prior or Omnibus approval of Audit Committee for all	23(2), (3)	Yes	
Approval for material related party transactions	23(4)	Yes	
Disclosure of related party transactions on consolidated basis	23(9)	Yes	
Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes	
Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2), (3), (4), (5) & (6)	Not Applicable	
Annual Secretarial Compliance Report	24(A)	Yes	
Alternate Director to Independent Director	25(1)	Not Applicable	
Maximum Tenure	25(2)	Yes	
Meeting of independent directors	25(3) & (4)	Yes	
Familiarization of independent directors	25(7)	Yes	
Declaration from Independent Director	25(8) & (9)	Yes	
D & O Insurance for Independent	25(10)	Not Applicable	
Memberships in Committees	26(1)	Yes	
Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
Disclosure of Shareholding by Non-Executive Directors	26(4)	Yes	
Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	

Other Information	
--------------------------	--

III Affirmations:

The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied. - **Yes**

Other Information	
--------------------------	--

Name : **Swati Vijan**
Designation : **Company Secretary**

ANNEXURE IV

Confidential

%symbol%	%companyName%	%quarterEnded%
----------	---------------	----------------

(A) Any loan or any other form of debt advanced by the listed entity directly or indirectly to

Aggregate amount advanced during six months				Balance outstanding at the end of six months			
<i>Promoter or any other entity controlled by them</i>	<i>Promoter Group or any other entity controlled by them</i>	<i>Directors (including relatives) or any other entity controlled by them</i>	<i>KMPs or any other entity controlled by them</i>	<i>Promoter or any other entity controlled by them</i>	<i>Promoter Group or any other entity controlled by them</i>	<i>Directors (including relatives) or any other entity controlled by them</i>	<i>KMPs or any other entity controlled by them</i>

(B) Any guarantee/ comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

Entity	Type (guarantee, comfort letter etc.)	Aggregate amount of issuance during six months	Balance outstanding at the end of six months (taking into account any invocation)
<i>Promoter or any other entity controlled by them</i>			
<i>Promoter Group or any other entity controlled by them</i>			
<i>Directors (including relatives) or any other entity controlled by them</i>			
<i>KMPs or any other entity controlled by them</i>			

(C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

Entity	Type of Security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
<i>Promoter or any other entity controlled by them</i>			
<i>Promoter Group or any other entity controlled by them</i>			
<i>Directors (including relatives) or any other entity controlled by them</i>			
<i>KMPs or any other entity controlled by them</i>			

(D) If the Listed Entity would like to provide any other information the same may be indicated here

--

Affirmations

All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company

Company Remarks in case of non-compliant status

--

Name: Jasjot Singh
Designation: Chief Financial Officer
Place: Mohali
Date: 14-Apr-2023

ANNEXURE II

Attachment for details of material Related Party transactions

S. No.	Name of the Related Party	Nature of Relation	Nature of Transactions
01	Healthy Biosciences Private Limited	Company is a Promoter of Ajooni Biotech Limited.	Contract for purchase & sale of goods shall be on a continuous basis. Further, leasing of properties on yearly basis.
02	Punjab Biotechnology Park Limited	Mr. Jasjot Singh, being common Director in Ajooni Biotech Limited and Punjab Biotechnology Park Limited	Contract for purchase & sale of goods shall be on a continuous basis.
03	M/s. Khanna Solvex	Mr. Jasjot Singh, Partner in the firm.	Contract for purchase & sale of goods shall be on a continuous basis.
04	Mr. Jasjot Singh	Managing Director of Ajooni Biotech Limited	Expenses incurred/ Rent paid on our behalf or any repayment made
05	Mr. Gursimran Singh	Director of Ajooni Biotech Limited	Expenses incurred/ Rent paid on our behalf or any repayment made
06	Mr. Partek Singh	Director of Ajooni Biotech Limited	Expenses incurred/ Rent paid on our behalf or any repayment made